Exagen Inc. Common Stock (XGN)
Stock · NASDAQ · Health Care
$7.74as of 10/16/2026
Price chart
Active signals
XGN Signal Track Record
How signals performed across all stocks →What XGN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 50 | +2.1% | 52% | October 2, 2026 |
| Bollinger Band Breakout | 26 | +8.6% | 62% | September 18, 2026 |
| Bollinger Band BreakdownActive now | 19 | -11.7% | 42% | July 13, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -9.8% | 38% | December 1, 2025 |
| Any 20-session window (baseline) | +0.1% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About XGN
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 216
- Website
- exagen.com/
Fundamentals
- 1-day range
- $7.3$8.55
- Market cap
- $159.64M
- P/E (trailing)
- —
- P/E (forward)
- -16.43
- EPS (trailing)
- $-0.81
- Dividend yield
- —
- Beta
- 2.28
- Avg. volume
- 344.8K
How Exagen Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 10, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Exagen Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- XGNExagen Inc. Common Stock$7.72▼ 9.81%Market cap $159.64MP/E —$2.59$12.23
- YDESYD Bio Limited Ordinary Shares$5.92▼ 12.17%Market cap $167.45MP/E —$1.7$22
- KEQUKewaunee Scientific Corporation Common Stock$32.93▲ 2.30%Market cap $108.73MP/E 11.26$32$46.57
- TLSIWTriSalus Life Sciences Inc. Warrant$0.8799▼ 2.23%Market cap $101.95MP/E —$0.4405$1.85
- ACHAccendra Health Inc. Common Stock$0.24▼ 7.69%Market cap $223.62MP/E —$0.2615$5.6
- BNRBurning Rock Biotech Limited American Depositary Shares$12.9▼ 17.31%Market cap $93.65MP/E —$6.79$41.72
- BDSXBiodesix Inc. Common Stock$23.66▼ 4.25%Market cap $228.86MP/E —$5.26$31.97
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| XGN Exagen Inc. Common Stock | $159.64M | — | $7.72 | ▼ 9.81% | $2.59$12.23 |
| YDES YD Bio Limited Ordinary Shares | $167.45M | — | $5.92 | ▼ 12.17% | $1.7$22 |
| KEQU Kewaunee Scientific Corporation Common Stock | $108.73M | 11.26 | $32.93 | ▲ 2.30% | $32$46.57 |
| TLSIW TriSalus Life Sciences Inc. Warrant | $101.95M | — | $0.8799 | ▼ 2.23% | $0.4405$1.85 |
| ACH Accendra Health Inc. Common Stock | $223.62M | — | $0.24 | ▼ 7.69% | $0.2615$5.6 |
| BNR Burning Rock Biotech Limited American Depositary Shares | $93.65M | — | $12.9 | ▼ 17.31% | $6.79$41.72 |
| BDSX Biodesix Inc. Common Stock | $228.86M | — | $23.66 | ▼ 4.25% | $5.26$31.97 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- TD Cowen Maintains Buy on Exagen, Raises Price Target to $11benzinga · 10/13/2026
- Full Transcript: Exagen Q2 2026 Earnings CallBenzinga · 9/17/2026
Insider Activity
Insider Actions →- Black Jeffrey G. · September 1, 2026 · Grant1.6K @ $3.02
- Black Jeffrey G. · September 1, 2026 · Sale20.6K @ $7.22
- Kim Paul · June 9, 2026 · Grant37.5K
- KAHN SCOTT D · June 9, 2026 · Grant37.5K
- McKhann Chas · June 9, 2026 · Grant37.5K
- Robertson Bruce C · June 9, 2026 · Grant37.5K
- Frank Stokes · June 9, 2026 · Grant37.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 9.57M
- Total value held
- $25.89M
- Institutional holders
- 58
- Unknown796.6K
- Unknown792.9K
- Unknown689.1K
- Unknown678.7K
- Unknown585.0K
- Unknown537.9K
- Unknown493.7K
- Unknown439.9K
- Unknown395.2K
- Unknown369.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
TD Cowen Raises Exagen Price Target to $11
TD Cowen has maintained its positive stance on Exagen, raising its price target to $11. This update aligns with the broader analyst consensus, where the average target sits at $10.14. The move provides context for the stock's current position within its 52-week range of $2.59 to $12.23.
TD Cowen Raises Exagen Price Target to $11. TD Cowen has maintained its positive stance on Exagen, raising its price target to $11. This update aligns with the broader analyst consensus, where the average target sits at $10.14. The move provides context for the stock's current position within its 52-week range of $2.59 to $12.23.